

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM410533

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Nexcyon Pharmaceuticals, Inc.		12/27/2016	Corporation: WISCONSIN
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Pegasus Laboratories, Inc.		
<b>Street Address:</b>	1217 W. 12th Street		
<b>City:</b>	Kansas City		
<b>State/Country:</b>	MISSOURI		
<b>Postal Code:</b>	64101		
<b>Entity Type:</b>	Corporation: MISSOURI		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3330512	RECONCILE	
<b>Registration Number:</b>	3558049	BOND	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3122076400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	312-207-1000		
<b>Email:</b>	mbenson@reedsmith.com		
<b>Correspondent Name:</b>	Robert E. Browne		
<b>Address Line 1:</b>	Reed Smith LLP		
<b>Address Line 2:</b>	10 South Wacker Drive, 40th Floor		
<b>Address Line 4:</b>	Chicago, ILLINOIS 60606		
<b>NAME OF SUBMITTER:</b>	Robert E. Browne		
<b>SIGNATURE:</b>	/Robert E. Browne/		
<b>DATE SIGNED:</b>	12/29/2016		
<b>Total Attachments: 8</b>			
source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page1.tif			
source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page2.tif			
source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page3.tif			
source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page4.tif			

OP \$65.00 3330512

source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page5.tif

source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page6.tif

source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page7.tif

source=Trademark Assignment from Nexcyon Pharmaceuticals, Inc#page8.tif

## INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

---

This Intellectual Property Assignment Agreement (this "*IP Assignment*"), is made and entered into as of December 27, 2016, by and between Nexcyon Pharmaceuticals, Inc., a Wisconsin corporation (the "*Assignor*"), and Pegasus Laboratories, Inc., a Missouri corporation (the "*Assignee*"). Capitalized terms not otherwise defined herein shall have the meaning set forth in that certain Asset Purchase Agreement, dated December 27, 2016, by and between Assignor and Assignee (the "*Purchase Agreement*").

### RECITAL

WHEREAS, Assignor desires to assign to Assignee, and Assignee desires to accept and assume from Assignor, all of Assignor's right, title, interest, and obligations of the Intellectual Property Assets, as set forth in Exhibit A.

### AGREEMENT

NOW, THEREFORE, the parties agree as follows:

- 1. Recital.** The Recital hereto are hereby incorporated by reference.
- 2. Assignment and Assumption.** Assignor hereby assigns, transfers and conveys to Assignee all of Assignor's right, title, interest, and obligations in the Intellectual Property Assets, and the Assignee hereby assumes and accepts the foregoing assignment of all of the right, title, interest, and obligations of the Assignor in and to the Intellectual Property Assets.
- 3. Binding Effect.** This IP Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.
- 4. Miscellaneous.** This IP Assignment may be executed in any number of counterparts, each of which will be deemed an original, but all of which together constitute one and the same instrument. A facsimile or electronic copy of this IP Assignment and any signatures hereon shall be considered for all purposes as original. This IP Assignment shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule. The parties hereby undertake that they will execute such documents and take such actions as may be reasonably required in order to confirm and further effectuate the provisions of this IP Assignment.

[Signature Page Follows]

IN WITNESS WHEREOF, the Assignor has caused this IP Assignment to be executed as of the date first set forth above.

ASSIGNOR:

ASSIGNEE:

NEXCYON PHARMACEUTICALS, INC.

PEGASUS LABORATORIES, INC.

By:   
Terrence P. Clark  
President and CEO

By: \_\_\_\_\_  
Donald A. Chew  
President and CEO

IN WITNESS WHEREOF, the Assignor has caused this IP Assignment to be executed as of date first set forth above.


ASSIGNOR:

NEXCYON PHARMACEUTICALS, INC.

By: \_\_\_\_\_  
Terrence P. Clark  
President and CEO

ASSIGNEE:

PEGASUS LABORATORIES, INC.

By:  \_\_\_\_\_  
Donald A. Chew  
President and CEO

Intellectual Property Agreement

TRADEMARK

REEL: 005958 FRAME: 0613

Exhibit A

To the Form of Intellectual Property Assignment Agreement

Schedule of Trademarks

Trademark Name	Registration Number	Class	Country	Listed Owner	Registration Date	Renewal Date	Product Uses	Additional Notes
Bond	1177577	35	Australia <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	5/21/2007	5/21/2017	Promoting awareness among dog owners and veterinarians for improving behavior in dogs suffering from anxiety.	Assignment to Nexcyon Pharmaceuticals, Inc. was recorded effective 5/11/2014.
Reconcile	989184	5	Australia	Nexcyon Pharmaceuticals, Inc.	2/16/2004	2/16/2024	Veterinary preparations.	Assignment to Nexcyon Pharmaceuticals, Inc. was recorded effective 5/11/2014.
Reconcile	67611	5	Bulgaria <sup>1</sup>	Eli Lilly and Company (See additional notes)	1/25/2007	1/25/2017	Veterinary medicine, and specialization for anxiety of unrest and disturbances central nervous system in domestic animals.	Unable to verify assignment. Product uses were translated through Google@ Translate.
Bond	TMA773880	1	Canada <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	8/6/2010	8/4/2025	Promoting awareness among dog owners and veterinarians for improving behavior in dogs suffering from anxiety.	Assignment recorded on 11/20/2014. The class of goods was found with the Canadian Trademark Search database.
Reconcile	TMA773678	1	Canada	Nexcyon Pharmaceuticals, Inc.	8/4/2010	8/4/2025	Veterinary preparations, namely treatments for anxiety and central nervous system disorders in companion animals.	Assignment recorded on 11/20/2014. The class of goods was found with the Canadian Trademark Search database.
Bond	5962071	35, 41, 44	Community Trademark <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	4/17/2008	5/21/2017	Class 35: Promoting awareness among dog owners and veterinarians for improving behavior in dogs	Assignment to Nexcyon Pharmaceuticals, Inc. was recorded

TRADEMARK

REEL: 005958 FRAME: 0614

Trademark Name	Registration Number	Class	Country	Listed Owner	Registration Date	Renewal Date	Product Uses	Additional Notes
							suffering from anxiety; promotional services in respect of dog behavior, anxiety and/or illness. Class 41: Providing educational and training services and training advice and consultancy in respect of dogs, including in respect of behavior and/or in respect of anxiety; animal training for improving behavior in dogs, including dealing with anxiety in dogs. Class 44: Provision of veterinary information and advice concerning illnesses of dogs, including anxiety disorders; veterinary information, advice and consultancy in respect of dogs.	effective 11/10/2014.
Reconcile	3677416	5	Community Trademark	Nexcyon Pharmaceuticals, Inc.	7/8/2005	2/29/2024	Veterinary Preparations	Assignment to Nexcyon Pharmaceuticals, Inc. was recorded effective 11/10/2014.
Bond	5199219	41	Japan	Nexcyon Pharmaceuticals, Inc.	1/23/2009	1/23/2019	Teaching dog owners and veterinarians about improving behavior in dogs suffering from anxiety. Arranging conducting and organization of seminars for dog owners and veterinarians on improving behavior in dogs suffering from anxiety.	Assignment to Nexcyon Pharmaceuticals, Inc. was recorded 10/16/2014. Power of Attorney entered appointing Asamura Patent Office as POA.
Reconcile	4809586	5	Japan	Nexcyon	10/8/2004	10/8/2014	(No translation)	Unable to verify if

TRADEMARK

REEL: 005958 FRAME: 0615

Trademark Name	Registration Number	Class	Country	Listed Owner	Registration Date	Renewal Date	Product Uses	Additional Notes
in Katakana				Pharmaceuticals, Inc.				this registrations was renewed. Assignment to Nexcyon Pharmaceuticals, Inc. was recorded 10/16/2014. Power of Attorney entered appointing Asamura Patent Office as POA.
Reconcile in Katakana	5215525	5	Japan	Nexcyon Pharmaceuticals, Inc.	3/19/2009	3/19/2019	Veterinary preparations, namely, treatments for anxiety and central nervous system disorders in companion animals.	Assignment to Nexcyon Pharmaceuticals, Inc. was recorded 10/16/2014. Power of Attorney entered appointing Asamura Patent Office as POA.
Reconcile	4804573	5	Japan	Nexcyon Pharmaceuticals, Inc.	9/17/2004	9/17/2014	(No translation)	Unable to verify if this registrations was renewed. Assignment to Nexcyon Pharmaceuticals, Inc. was recorded 10/16/2014. Power of Attorney entered appointing Asamura Patent Office as POA.
Bond	241847	35	Norway	Nexcyon Pharmaceuticals, Inc.	11/1/2007	11/1/2017	Promoting awareness among dog owners and veterinarians for improving behavior in dogs suffering from anxiety.	Assignment recorded on 10/29/2014.

TRADEMARK

REEL: 005958 FRAME: 0616



Trademark Name	Registration Number	Class	Country	Listed Owner	Registration Date	Renewal Date	Product Uses	Additional Notes
Reconcile	239684	5	Norway <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	6/15/2007	6/15/2017	Veterinary preparations, namely treatments for anxiety and central nervous system disorders in companion animals.	Assignment recorded on 10/29/2014.
Reconcile	83694	5	Romania <sup>1</sup>	Eli Lilly and Company (See additional notes)	1/25/2007	1/25/2017	Veterinary preparations, namely, treatments for anxiety and central nervous system disorders in companion animals.	Unable to verify assignment. Uses on this spreadsheet were translated by Google® Translate.
Bond	562488	35, 41	Switzerland <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	9/18/2007	9/18/2017	Class 35: Public relations for promoting awareness of dog owners and veterinarians for improving the behavior of dogs suffering from anxiety. Class 41: Providing educational and training services, advice and consultancy in respect of dogs, including in respect of behavior or anxiety.	Assignment recorded on 10/29/2014.
Reconcile	557081	5	Switzerland <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	4/13/2007	1/25/2017	Veterinary preparations, namely preparations for the treatment of anxiety and diseases or disorders of the central nervous system in companion animals.	Assignment recorded on 10/29/2014.
Bond	2456203	35, 41, 44	United Kingdom <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	3/28/2008	5/21/2017	Class 35: Promoting awareness among dog owners and veterinarians for improving behavior in dogs suffering from anxiety. Class 41: Providing educational and training services, advice and consultancy in respect of	Assignment recorded on 10/29/2014.

TRADEMARK

REEL: 005958 FRAME: 0617

Trademark Name	Registration Number	Class	Country	Listed Owner	Registration Date	Renewal Date	Product Uses	Additional Notes
Reconcile	2444689	5	United Kingdom <sup>1</sup>	Nexcyon Pharmaceuticals, Inc.	7/27/2007	1/25/2017	dogs, including in respect of behavior and/or respect of anxiety. Class 44: Provision of veterinary information and advice concerning illnesses of dogs, including anxiety disorders; veterinary information, advice and consultancy services in respect of dogs; improving behavior in dogs, including dealing with anxiety in dogs.	Assignment recorded on 10/29/2014.
Bond	3558049	41	United States	Nexcyon Pharmaceuticals, Inc.	1/6/2019	1/6/2019	Veterinary preparations, including treatments for anxiety and central nervous system disorders in companion animals and pets. Promoting awareness among dog owners and veterinarians for improving behavior in dogs suffering from anxiety by providing information on pet training.	Assignment recorded on 2/26/2015 with the USPTO
Reconcile	3330512	5	United States	Nexcyon Pharmaceuticals, Inc.	11/6/2007	11/6/2017	Veterinary preparations, namely treatments for anxiety and central nervous system disorders in companion animals.	Assignment recorded on 2/26/2015 with the USPTO